NCT03876301 - Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions

Blood Coagulation DisorderBlood Coagulation Disorders, InheritedCoagulation Protein DisordersHemophilia AGenetic Diseases, InbornGenetic Diseases, X-LinkedHematologic DiseasesHemorrhagic DisordersFactor VIII Deficiency

Interventions

DRUG

Standard of Care FVIII Replacement therapy

There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.

Trial Locations (11)

3004

The Alfred Hospital, Melbourne

6150

Fiona Stanley Hospital, Murdoch

10400

Ramathibodi Hospital, Mahidol University, Bangkok

30322

Emory University, Atlanta

32610

University of Florida, Gainesville

39110

Mississippi Center for Advanced Medicine, Madison

48201

Children's Hospital of Michigan, Detroit

94117

University of California San Francisco, San Francisco

98104

Bloodworks Northwest, Seattle

V621Y6

Providence Hematology/St. Paul's Hosptial, Vancouver

L8N3Z5

McMaster University / Royal Prince Alfred Hospital, Hamilton

All Listed Sponsors

lead

Spark Therapeutics, Inc.

INDUSTRY